Alnylam Pharmaceuticals, Inc. vs Merck & Company, Inc. — Stock Comparison

ALNY
Alnylam Pharmaceuticals, Inc.
$296.11
▼ 4.32%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
Alnylam Pharmaceuticals, Inc.
ALNY8/10vs 6.7/10

Q·Score Breakdown

8
Bullish
Overall
6.7
Neutral
8.2
Quality
6.2
6.2
Health
7
8
Growth
6.2
9.7
Valuation
7.2
7.5
Sentiment
7.1
ALNY

Consensus analyst target of $449.48 is 52% above current price.

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

BUY
Target $449.48 (+51.8%)
25 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

ALNY
MRK
74.6×
Trailing P/E
31.5×
21.2×
Forward P/E
11.5×
12.6%
Profit Margin
13.6%
80.8%
Gross Margin
76.6%
90.4%
ROE
96.4%
Revenue Growth
4.9%
Earnings Growth
0.38
Beta
0.28
Price / Book
$39.5B
Market Cap
$277.0B
$246 – $496
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →